SCHEMBL224655

SCHEMBL224655

CCOC(=O)c1ccc2c(c1)C(=O)CC(C)N2C(C)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
SRD5A1 P18405 1/20 0.44
SRD5A2 P31213 1/20 0.44
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
MAPT P10636 2/20 0.40
PRMT1 Q99873 1/20 0.40
HTR7 P34969 2/20 0.40
NOTUM Q6P988 1/20 0.40
ATM Q13315 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PABPC1 P11940 1/20 0.39
APOBEC3A P31941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL221901 1.00 ALDH1A1 (0.46) ALDH1A1MAPK1SMN1; SMN2SRD5A1SRD5A2
SCHEMBL15890864 0.82 NOTUM (0.46) CA1CA2CA9MAPTNOTUM
SCHEMBL5712019 0.79 NOTUM (0.50) ALDH1A1MAPK1SMN1; SMN2SRD5A1SRD5A2
SCHEMBL224343 0.76 BRD4 (0.46) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL225279 0.76 BRD4 (0.46) ALDH1A1SMN1; SMN2CA12CA1CA2
SCHEMBL28017329 0.76 ALDH1A1 (0.46) ALDH1A1MAPK1SRD5A1SRD5A2CA12
SCHEMBL225187 0.76 LMNA (0.50) ALDH1A1MAPTNOTUM
SCHEMBL20288980 0.76 NOTUM (0.47) SMN1; SMN2MAPTNOTUM
SCHEMBL223531 0.76 NOTUM (0.47) ALDH1A1MAPTNOTUMHTTTP53
SCHEMBL24347596 0.75 SRD5A1 (0.45) ALDH1A1MAPK1SMN1; SMN2SRD5A1SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045423-B2 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient KOWA COMPANY, LTD. (JP) 2015-06-02 US disclosed
US-20140249144-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT KOWA COMPANY, LTD. (JP) 2014-09-04 US disclosed
US-8791090-B2 Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient KOWA COMPANY, LTD. (JP) 2014-07-29 US disclosed
EP-2415764-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT Kowa Company, Ltd. (JP) 2012-02-08 EP disclosed
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT KOWA COMPANY, LTD. (JP) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249144-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT EPOR, HBG1, HBG2 ALDH1A1 1491/4885MAPK1 1726/4885SMN1; SMN2 2091/4885
US-20120004197-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT EPOR, HBG1, HBG2 ALDH1A1 1491/4885MAPK1 1726/4885SMN1; SMN2 2091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.